Efficacy and Safety of GLP-1 Receptor Agonists for MASLD: An Umbrella Review

Twenty-three meta-analyses and systematic reviews were included in an umbrella review assessing the efficacy and safety of GLP-1 receptor agonists for Metabolic dysfunction-associated steatotic liver disease (MASLD). The review, authored by Hui Wu and last updated in May 2026, summarizes outcomes into five categories: liver characteristics, enzyme levels, anthropometric measurements, metabolic markers, and inflammatory markers. It is shared under a CC-BY-4.0 license as an 8.7 MB DOCX file on figshare.

Use Cases

• Summarizing evidence on liver characteristic improvements based on the five outcome categories mentioned in the description.
• Assessing the safety profile of GLP-1 receptor agonists based on the review's safety analysis.
• Identifying gaps in evidence quality based on the reported assessment of included reviews using AMSTAR 2.
• Hypothesis generation for future clinical trials based on the preliminary findings described.

Strengths

• Includes 23 meta-analyses and systematic reviews, providing a synthesized evidence base.
• Follows PRISMA 2020 guidance for systematic review methodology.
• Assesses evidence quality using the AMSTAR 2 tool.

Limitations

• Nearly 80% of the included systematic reviews are reported to be of critically low quality with high evidence overlap.
• The findings are described as preliminary and hypothesis-generating, indicating limited conclusive evidence.
• Column-level documentation is absent; field semantics must be inferred after download.

Provenance

Source

figshare, author Hui Wu.

Collection Method

A novel umbrella review searching five databases from inception to 30 September 2025.

Time Range

Literature search covered from database inception to September 30, 2025.

Freshness

Last updated 2026-05-28 04:51:27.